Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: Where are we now and where do we go from here?

Haematologica

Volumn 92, Issue 12, 2007, Pages 1596-1598

  Efficace, Fabio ^a,b   Novik, Andrei ^c   Vignetti, Marco ^a   Mandelli, Franco ^a,b   Cleeland, Charles S ^d  

^a Italian Group for Adult Hematologic Diseases GIMEMA Data Center   (Italy)

^b International Centre for Transplantation in Thalassemia and Sickle Cell Anemia   (Italy)

^c Pirogov National Medical Surgical Center   (Russian Federation)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL RESEARCH; DISEASE COURSE; EDITORIAL; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; MORBIDITY; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG EVALUATION; HEMATOLOGIC NEOPLASMS; HUMANS; PATIENT PARTICIPATION; QUALITY OF LIFE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 37049020695     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11710     Document Type: Editorial

References (17)

1. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985;69:1155-9.
2. de Haes JC. Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C, editors. Psychosocial Oncology. Oxford: Pergamon Press; 1988. p. 61-70.
3. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004;13:115-38.
4. Federal Register, Vol. 71, No. 23; Friday, February 3, 2006.
5. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision-making? J Clin Oncol 2003;21:3502-11.
6. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006;24:3178-86.
7. Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Cancer 1999; 35:1565-70.
8. Kirkova J, Davis MP, Walsh D, Tiernan E, O'Leary N, LeGrand SB, et al, Cancer symptom assessment instruments: a systematic review. J Clin Oncol 2006;24:1459-73.
9. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al., The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76.
10. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 2007; 18: 775-81.
11. Molica S. Quality of life in chronic lymphocytic leukemia: a neglected issue. Leuk Lymphoma 2005;46:1709-14.
12. Burge PS, Prankerd TA, Richards JD, Sare M, Thompson DS, Wright P. Quality and quantity of survival in acute myeloid leukaemia. Lancet 1975;2:621-4.
13. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984; 2:865-70.
14. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21:2138-46.
15. Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M. German CLL Study Group. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 2007; 25:1722-31.
16. Brundage M, Leis A, Bezjak A, Feldman-Stewart D, Degner L, Velji K, et al. Cancer patients' preferences for communicating clinical trial quality of life information: a qualitative study. Qual Life Res 2003;12:395-404.
17. Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 2004; 22:1721-30.